Asieris Pharmaceuticals Enters an Exclusive Licensing Agreement with Theramex for CEVIRA® subject to certain conditions, Advancing the Global Development and Commercialization of a Non-Surgical Treatment for Cervical Precancerous Lesions in Europe
Agreement is expected to grant Theramex exclusive rights to CEVIRA ® in Europe, Australia, New Zealand and Turkey, while Asieris retains rights for the rest of the world. The deal includes 15 million US dollars of upfront payment and a total of 11...
Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib
SHANGHAI, July 7, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today...
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immune-mediated kidney diseases Civorebrutinib adds pipeline-in-a-product potential across multiple...